001.01^18547545^111_TEST000123A^^201206170000-0500^^1^^5671-3^Lead [Mass/volume] in Blood^^H^^^ug/dL^F^^SP004X10987^^^20120615^^111_TEST000123A_OBS_1_RES_1^^^^20120617^Raja Rami Varma JR DR PHD^111^NIST_Sending_App^2.16.840.1.113883.3.72.5.21^01D1111111^Atomic Absorption Spectrophotometry^
001.02^18568545^112_TEST0001365^^201208060000-0500^^1^^1742-6^Alanine aminotransferase [Enzymatic activity/Volume] in Serum or Plasma^^H^^^U/L^F^^SP004345987^^^20120806^^112_TEST0001365_OBS_1_RES_1^^^^20120806^Raja Rami Varma JR DR PHD^121^NIST_Sending_App^2.16.840.1.113883.3.72.5.21^01D2121212^Spectrophotometry^
001.03^18789547^113_3456723^^201208021600-0500^^1^^24467-3^CD3+CD4+ (T4 helper) cells [#/volume] in Blood^^L^^^{Cells}/uL^F^^SP004X10723^^^20120801^^113_3456723_OBS_1_RES_1^^^^201208021100-0500^Raja Rami Varma JR DR PHD^131^NIST_Sending_App^2.16.840.1.113883.3.72.5.21^01D7654321^Flow Cytometry (FC)^
002.01^12346^211_PN-F20120325-1^^20120328140000-0500^^1^^5609-3^Cadmium [Mass/volume] in Blood^^H1^^^ug/L^F^^PNS-20120325-V03^^^20120325^^211_PN-F20120325-1_OBS_1_RES_1^^^^201203281400-0500^^^^^211_none^^
002.02^12346^212_PN-F20120325-1^^201208020400-0500^^1^^5609-3^Cadmium [Mass/volume] in Blood^^H^^^ug/L^F^^SP-20120729-C1^^^20120729^^212_PN-F20120325-1_OBS_1_RES_1^^^^20120802^^^^^22D2212212^^
002.03^12346^213_PN-F20120325-1^^201205120300-0500^^1^^5671-3^Lead [Mass/volume] in Blood^^H^^^ug/dL^F^^20120511V3303^^^20120511^^213_PN-F20120325-1_OBS_1_RES_1^^^^20120512^^^^^22D2312312^^
003.01^PATID1234^311_ORD723222-4^^20110601123500.000-0500^^1^^625-4^Bacteria identified in Stool by Culture^^^^^^P^^ORD723222-4^^^20110528123500-0500^^311_ORD723222-4_OBS_1_RES_1^^^^20110530123500.000-0500^^^^^03D3113113^^
003.01^PATID1234^311_ORD723222-4^^20110601123500.000-0500^^2^^625-4^Bacteria identified in Stool by Culture^^^^^^P^^ORD723222-4^^^20110528123500-0500^^311_ORD723222-4_OBS_1_RES_2^^^^20110601123500.000-0500^^^^^03D3113113^^
003.02^PATID123487^312_ORD723225^^201207100230-0500^^1^^6463-4^Bacteria identified in Unspecified specimen by Culture^^^^^^P^^Sp723222-4^^^201207081200^^312_ORD723225_OBS_1_RES_1^^^^20110530123500.000-0500^^^^^10D0290071^^
003.02^PATID123487^312_ORD723225^^201207100230-0500^^2^^6463-4^Bacteria identified in Unspecified specimen by Culture^^^^^^P^^Sp723222-4^^^201207081200^^312_ORD723225_OBS_1_RES_2^^^^201207100230^^^^^10D0290071^^
003.03^2012BJ123498^313_ORD72387593^^201208201030-0500^^1^^6463-4^Bacteria identified in Unspecified specimen by Culture^^^^^^P^^SPX7231522^^^20120818^^313_ORD72387593_OBS_1_RES_1^^^^20120820^^^^^10D2036903^^
003.03^2012BJ123498^313_ORD72387593^^201208201030-0500^^2^^6463-4^Bacteria identified in Unspecified specimen by Culture^^^^^^P^^SPX7231522^^^20120818^^313_ORD72387593_OBS_1_RES_2^^^^20120820^^^^^10D2036903^^
004.01^PATID1234^411_ORD723222-4-1^^201106010900-0500^^1^^625-4_1^Bacteria identified in Stool by Culture^^^^^^F^^ORD723222-4^^^20110528^^411_ORD723222-4_OBS_1_RES_1^^^^20110531130655-0500^^^^^987^^
004.01^PATID1234^411_ORD723222-4-2^^201106010900-0500^^2^^20-8^Amoxicillin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC)^^I^^^ug/mL^F^^ORD723222-4.1^^^20110528^^411_ORD723222-4_OBS_2_RES_2^^^^201106010900-0500^^^^^987^^
004.01^PATID1234^411_ORD723222-4-2^^201106010900-0500^^3^^516-5^Trimethoprim+Sulfamethoxazole [Susceptibility] by Minimum inhibitory concentration (MIC)^^R^^^ug/mL^F^^ORD723222-4.1^^^20110528^^411_ORD723222-4_OBS_2_RES_3^^^^201106010900-0500^^^^^987^^
004.01^PATID1234^411_ORD723222-4-2^^201106010900-0500^^4^^185-9^Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^ORD723222-4.1^^^20110528^^411_ORD723222-4_OBS_2_RES_4^^^^201106010900-0500^^^^^987^^
004.02^PATID1234^412_VM8907334-1^^20120422000000-0600^^1^^11475-1^Microorganism identified in Unspecified specimen by Culture^^^^^^F^^S20129876997^^^20120315^^412_VM8907334_OBS_1_RES_1^^^^20120415^^^^^42D7654321^^
004.02^PATID1234^412_VM8907334-2^^20120422000000-0600^^2^^48177-0^Streptomycin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria^^S^^^[arb'U]^F^^S20129876997-7^^^20120315^^412_VM8907334_OBS_2_RES_1^^^^20120422^^^^^42D7654321^^
004.02^PATID1234^412_VM8907334-2^^20120422000000-0600^^3^^25217-1^Isoniazid 0.1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria^^R^^^[arb'U]^F^^S20129876997-7^^^20120315^^412_VM8907334_OBS_2_RES_2^^^^20120422^^^^^42D7654321^^
004.02^PATID1234^412_VM8907334-2^^20120422000000-0600^^4^^25202-3^Rifampin 1 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria^^S^^^[arb'U]^F^^S20129876997-7^^^20120315^^412_VM8907334_OBS_2_RES_3^^^^20120422^^^^^42D7654321^^
004.02^PATID1234^412_VM8907334-2^^20120422000000-0600^^5^^25194-2^Ethambutol 5 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria^^S^^^[arb'U]^F^^S20129876997-7^^^20120315^^412_VM8907334_OBS_2_RES_4^^^^20120422^^^^^42D7654321^^
004.03^P12345887^413_ORD2113586-3-1^^201206170842-0500^^01^^6463-4^Bacteria identified in Unspecified specimen by Culture^^^^^^F^^s201206-34598-1^^^20120612^^413_ORD2113586-3_OBS_1_RES_1^^^^20120616^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^02^^20-8^Amoxicillin+Clavulanate [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_1^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^03^^141-2^Ceftriaxone [Susceptibility] by Minimum Inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_2^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^04^^193-3^Clindamycin [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_3^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^05^^108-1^Cefotaxime [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_4^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^06^^145-3^Cefuroxime Parenteral [Susceptibility] by Minimum inhibitory concentration (MIC)^^R^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_5^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^07^^233-7^Erythromycin [Susceptibility] by Minimum inhibitory concentration (MIC)^^R^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_6^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^08^^6644-9^Cefepime [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_7^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^09^^20396-8^Levofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_8^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^10^^6652-2^Meropenem [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_9^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^11^^6932-8^Penicillin [Susceptibility] by Minimum inhibitory concentration (MIC)^^R^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_10^^^^201206170842-0500^^^^^04D0290071^^
004.03^P12345887^413_ORD2113586-3-2^^201206170842-0500^^12^^524-9^Vancomycin [Susceptibility] by Minimum inhibitory concentration (MIC)^^S^^^ug/mL^F^^s201206-34598-1.4^^^20120612^^413_ORD2113586-3_OBS_2_RES_11^^^^201206170842-0500^^^^^04D0290071^^
005A.01^PATID1234^5A11_ORD723222^^20120629132900-0500^^1^^22314-9^Hepatitis A virus IgM Ab [Presence] in Serum^^^^^^F^^FILL35479^^^20120628070100^^5A11_ORD723222_OBS_1_RES_1^^^^20120628080500^^^^^34D4567890^^
005A.01^PATID1234^5A11_ORD723222^^20120629132900-0500^^2^^16933-4^Hepatitis B virus core Ab [Presence] in Serum^^^^^^F^^FILL35479^^^20120628070100^^5A11_ORD723222_OBS_1_RES_2^^^^20120628080500^^^^^34D4567890^^
005A.01^PATID1234^5A11_ORD723222^^20120629132900-0500^^3^^5195-3^Hepatitis B virus surface Ag [Presence] in Serum^^^^^^F^^FILL35479^^^20120628070100^^5A11_ORD723222_OBS_1_RES_3^^^^20120628080500^^^^^34D4567890^^
005A.01^PATID1234^5A11_ORD723222^^20120629132900-0500^^4^^13955-0^Hepatitis C virus Ab [Presence] in Serum by Immunoassay^^A^^^^F^^FILL35479^^^20120628070100^^5A11_ORD723222_OBS_1_RES_4^^^^20120628080500^^^^^34D4567890^^
005A.01^PATID1234^5A11_ORD723222^^20120629132900-0500^^5^^48159-8^Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay^^H2^^^{s_co_ratio}^F^In order to reduce the incidence of a false positive result, the CDC recommends that all s/co ratios between 1.0 and 10.9 be confirmed with additional Hepatitis C quantitative PCR testing. Quantification range of the PCR assay is 43-69,000,000 IU/mL .^FILL35479^^^20120628070100^^5A11_ORD723222_OBS_1_RES_5^^^^20120628080500^^^^^34D4567890^^
005A.01^PATID1234^5A11_ORD723222^^20120629132900-0500^^6^^11011-4^Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method^^H2^^^[IU]/mL^F^^FILL35479^^^20120628070100^^5A11_ORD723222_OBS_1_RES_6^^^^20120628092700^^^^^34D4567890^^
005A.03^SMB3948814^5A13_OR723222980^^20120603132900-0500^^1^^13955-0^Hepatitis C virus Ab [Presence] in Serum by Immunoassay^^A^^^^F^^FILL354795671^^^201206010701^^5A13_OR723222980_OBS_1_RES_1^^^^201206011316^^^^^22D4560000^^
005A.03^SMB3948814^5A13_OR723222980^^20120603132900-0500^^2^^48159-8^Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay^^H^^^{s_co_ratio}^F^^FILL354795671^^^201206010701^^5A13_OR723222980_OBS_1_RES_2^^^^201206011316^^^^^22D4560000^^
005A.03^SMB3948814^5A13_OR723222980^^20120603132900-0500^^3^^11011-4^Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method^^H^^^[IU]/mL^F^In order to reduce the incidence of a false positive result, the CDC recommends that all s/co ratios between 1.0 and 10.9 be confirmed with additional Hepatitis C quantitative PCR testing. Quantification range of the PCR assay is 43-69,000,000 IU/mL .^FILL354795671^^^201206010701^^5A13_OR723222980_OBS_1_RES_3^^^^201206011316^^^^^22D4560000^^
005B.01^PATID1234^5B11_ORD723222^^20120629132900-0500^^1^^22314-9^Hepatitis A virus IgM Ab [Presence] in Serum^^^^^^F^^FILL35479^^^20120628070100^^5B11_ORD723222_OBS_1_RES_1^^^^20120628080500^^^^^34D4567890^^
005B.01^PATID1234^5B11_ORD723222^^20120629132900-0500^^2^^16933-4^Hepatitis B virus core Ab [Presence] in Serum^^^^^^F^^FILL35479^^^20120628070100^^5B11_ORD723222_OBS_1_RES_2^^^^20120628080500^^^^^34D4567890^^
005B.01^PATID1234^5B11_ORD723222^^20120629132900-0500^^3^^5195-3^Hepatitis B virus surface Ag [Presence] in Serum^^^^^^F^^FILL35479^^^20120628070100^^5B11_ORD723222_OBS_1_RES_3^^^^20120628080500^^^^^34D4567890^^
005B.01^PATID1234^5B11_ORD723222^^20120629132900-0500^^4^^13955-0^Hepatitis C virus Ab [Presence] in Serum by Immunoassay^^A^^^^F^^FILL35479^^^20120628070100^^5B11_ORD723222_OBS_1_RES_4^^^^20120628080500^^^^^34D4567890^^
005B.01^PATID1234^5B11_ORD723222^^20120629132900-0500^^5^^48159-8^Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay^^H2^^^{s_co_ratio}^F^In order to reduce the incidence of a false positive result, the CDC recommends that all s/co ratios between 1.0 and 10.9 be confirmed with additional Hepatitis C quantitative PCR testing. Quantification range of the PCR assay is 43-69,000,000 IU/mL .^FILL35479^^^20120628070100^^5B11_ORD723222_OBS_1_RES_5^^^^20120628080500^^^^^34D4567890^^
005B.01^PATID1234^5B11_ORD723222-2^^20120629132900-0500^^6^^11011-4^Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method^^H2^^^[IU]/mL^F^^FILL35479^^^20120628070100^^5B11_ORD723222_OBS_2_RES_1^^^^20120628092700^^^^^34D4567890^^
005B.03^SMB3948814^5B13_OR723222980-1^^20120603132900-0500^^1^^13955-0^Hepatitis C virus Ab [Presence] in Serum by Immunoassay^^A^^^^F^^FILL354795671^^^201206010701^^5B13_OR723222980_OBS_1_RES_1^^^^201206011316^^^^^22D4560000^^
005B.03^SMB3948814^5B13_OR723222980-1^^20120603132900-0500^^2^^48159-8^Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay^^H^^^{s_co_ratio}^F^In order to reduce the incidence of a false positive result, the CDC recommends that all s/co ratios between 1.0 and 10.9 be confirmed with additional Hepatitis C quantitative PCR testing. Quantification range of the PCR assay is 43-69,000,000 IU/mL .^FILL354795671^^^201206010701^^5B13_OR723222980_OBS_1_RES_2^^^^201206011316^^^^^22D4560000^^
005B.03^SMB3948814^5B13_OR723222980-2^^20120603132900-0500^^3^^11011-4^Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe and target amplification method^^H^^^[IU]/mL^F^^FILL354795671^^^201206010701^^5B13_OR723222980_OBS_2_RES_1^^^^201206020927^^^^^22D4560000^^
006.01^PATID1234^611_OR980768901-1^^20120602133506-0500^^1^^6812-2^Dengue virus IgM Ab [Titer] in Serum^^H1^^^{titer}^F^^21543526^^^20120601095300^^611_OR980768901-1_RES_1^^^^20120602133006^^^^^66D6116116^^
006.02^PATID125789^612_2012-0987890001^^20111106101500-0600^^1^^31147-2^Reagin Ab [Titer] in Serum by RPR^^H^^^{titer}^F^^21543526^^^20111105143000-0600^^612_2012-0987890001_RES_1^^^^20111106100000-0600^^^^^04D1044168^^
006.03^PATID139948312^613_ord12-0987066712^^20120802111345-0500^^1^^33331-0^West Nile virus AB IgM, ELISA, Serum^^H^^^{titer}^F^^21543526^^^20120801^^613_ord12-0987066712_RES_1^^^^20120802^^^^^10D0270216^^
007.01^PATID1234^711_O12-897451-23^^201207120800-0800^^1^^23826-1^Bordetella pertussis DNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^This test was validated and its performance measures were determined to meet all local and federal requirements.^S1234^^^20120710^^711_O12-897451-23_RES_1^^^^201207110800^^^^^05D0599855^^
007.02^NJ2012-08556^712_TR09820981-2012^^201208082151-0600^^1^^40982-1^Influenza virus B RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^This test was validated and its performance measures were determined to meet all local and federal requirements.^SP2012-0987991-1^^^20120808^^712_TR09820981-2012_RES_1^^^^201208082151^^^^^07D7217217^^
007.03^PATID5678^713_Ord2012-568798-1^^201203170930-0600^^1^^48174-7^Mycobacterium tuberculosis complex rRNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^Includes M. tuberculosis, M. bovis, M microti, M. africanumare^VUL-S-2012-098733-3^^^20120316^^713_Ord2012-568798-1_RES_1^^^^20120317^^^^^07D7317317^^
008.01^WILJ2012-979952^811_Ord89017782^^201208021000-0600^^1^^43305-2^Neisseria gonorrhoeae rRNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^spm1245^^^20120731140000^^811_Ord89017782_RES_1^^^^201208021000^^^^^45D1086886^^
008.01^WILJ2012-979952^811_Ord89017782^^201208021000-0600^^2^^43304-5^Chlamydia trachomatis rRNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^spm1245^^^20120731140000^^811_Ord89017782_RES_2^^^^201208021000^^^^^45D1086886^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^01^^39528-5^Adenovirus DNA [Presence] in Unspecified specimen by Probe and target^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_1^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^02^^34487-9^Influenza virus A RNA [Presence] in Unspecified specimen by Probe and target^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_2^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^03^^49521-8^Influenza virus A H1 RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_3^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^04^^49524-2^Influenza virus A H3 RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_4^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^05^^40982-1^Influenza virus B RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_5^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^06^^29908-1^Parainfluenza virus 1 RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_6^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^07^^29909-9^Parainfluenza virus 2 RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_7^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^08^^29910-7^Parainfluenza virus 3 RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_8^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^09^^30075-6^Respiratory syncytial virus A RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_9^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^10^^30076-4^Respiratory syncytial virus B RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_10^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^11^^7993-9^Rhinovirus RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_11^^^^20120108215100-0600^^^^^08D8218218^^
008.02^P2008-706781-2^812_O2012-8711-12^^20120108215100-0600^^12^^38917-1^Human metapneumovirus RNA [Presence] in Unspecified specimen by Probe and target amplification method^^^^^^F^^S2012_987013^^^20120108-0600^^812_O2012-8711-12_RES_12^^^^20120108215100-0600^^^^^08D8218218^^
008.03^MJ200978990544^813_TPMG097865^^20120630210400-0800^^1^^20479-2^Measles virus IgG Ab [Presence] in Serum^^^^^^F^^2012s_4982-1^^^20120630114000-0800^^813_TPMG097865_RES_1^^^^20120630210400-0800^^^^^45D1086886^^
008.03^MJ200978990544^813_TPMG097865^^20120630210400-0800^^2^^21503-8^Measles virus IgM Ab [Presence] in Serum^^^^^^F^^2012s_4982-1^^^20120630114000-0800^^813_TPMG097865_RES_2^^^^20120630210400-0800^^^^^45D1086886^^
009.01^ShuA20120618-1^911_Ord123499^^201206211015-0800^^1^^6463-4^Bacteria identified in Unspecified specimen by Culture^Corynebacterium diphtheriae^^^^^F^An isolate cultured from this specimen has been submitted to the local Public Health Laboratory.^201206180179^^^20120618^^911_Ord123499_RES_1^^^^201206211015-0800^^^^^09D9119119^^
009.02^BB20120315-351^912_Ord68034987^^201204221630-0700^^1^^543-9^Mycobacterium sp identified in Unspecified specimen by Organism specific culture^^^^^^F^An isolate cultured from this specimen has been submitted to the local Public Health Laboratory.^2012031501992^^^20120315^^912_Ord68034987_RES_1^^^^20120422^^^^^09D9219219^^
009.03^NECS2012080-2^913_Ord12389600762^^201208101330-0800^^1^^11475-1^Microorganism identified in Unspecified specimen by Culture^^^^^^F^An isolate cultured from this specimen has been submitted to the local Public Health Laboratory.^20120808194^^^201208081500-0800^^913_Ord12389600762_RES_1^^^^201208101330-0800^^^^^05D0643085^^
